According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.

Anti-VEGF - Market

The global market for Anti-VEGF was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Anti-VEGF, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Anti-VEGF by region & country, by Type, and by Application.

The Anti-VEGF market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-VEGF.

Market Segmentation

Scope of Anti-VEGF - Market Report

Report Metric	Details
Report Name	Anti-VEGF - Market
Accounted market size in year	US$ 603 billion
CAGR	5%
Base Year	year
Segment by Type:	Avastin Lucentis Eylea
Segment by Application	Macular Edema Diabetic Retinopathy Retinal Vein Occlusion Age-Related Macular Degeneration
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Xbrane Biopharma AB, Allergan, Bayer AG, Regeneron Pharmaceuticals Inc., Viatris Inc. (Mylan)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Anti-VEGF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Anti-VEGF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Anti-VEGF in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Anti-VEGF - Market report?

Ans: The main players in the Anti-VEGF - Market are Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Xbrane Biopharma AB, Allergan, Bayer AG, Regeneron Pharmaceuticals Inc., Viatris Inc. (Mylan)

What are the Application segmentation covered in the Anti-VEGF - Market report?

Ans: The Applications covered in the Anti-VEGF - Market report are Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-Related Macular Degeneration

What are the Type segmentation covered in the Anti-VEGF - Market report?

Ans: The Types covered in the Anti-VEGF - Market report are Avastin, Lucentis, Eylea

1 Market Overview

1.1 Anti-VEGF Product Introduction

1.2 Global Anti-VEGF Market Size Forecast

1.2.1 Global Anti-VEGF Sales Value (2019-2030)

1.2.2 Global Anti-VEGF Sales Volume (2019-2030)

1.2.3 Global Anti-VEGF Sales Price (2019-2030)

1.3 Anti-VEGF Market Trends & Drivers

1.3.1 Anti-VEGF Industry Trends

1.3.2 Anti-VEGF Market Drivers & Opportunity

1.3.3 Anti-VEGF Market Challenges

1.3.4 Anti-VEGF Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Anti-VEGF Players Revenue Ranking (2023)

2.2 Global Anti-VEGF Revenue by Company (2019-2024)

2.3 Global Anti-VEGF Players Sales Volume Ranking (2023)

2.4 Global Anti-VEGF Sales Volume by Company Players (2019-2024)

2.5 Global Anti-VEGF Average Price by Company (2019-2024)

2.6 Key Manufacturers Anti-VEGF Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Anti-VEGF Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Anti-VEGF

2.9 Anti-VEGF Market Competitive Analysis

2.9.1 Anti-VEGF Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Anti-VEGF Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Avastin

3.1.2 Lucentis

3.1.3 Eylea

3.2 Global Anti-VEGF Sales Value by Type

3.2.1 Global Anti-VEGF Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Anti-VEGF Sales Value, by Type (2019-2030)

3.2.3 Global Anti-VEGF Sales Value, by Type (%) (2019-2030)

3.3 Global Anti-VEGF Sales Volume by Type

3.3.1 Global Anti-VEGF Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Anti-VEGF Sales Volume, by Type (2019-2030)

3.3.3 Global Anti-VEGF Sales Volume, by Type (%) (2019-2030)

3.4 Global Anti-VEGF Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Macular Edema

4.1.2 Diabetic Retinopathy

4.1.3 Retinal Vein Occlusion

4.1.4 Age-Related Macular Degeneration

4.2 Global Anti-VEGF Sales Value by Application

4.2.1 Global Anti-VEGF Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Anti-VEGF Sales Value, by Application (2019-2030)

4.2.3 Global Anti-VEGF Sales Value, by Application (%) (2019-2030)

4.3 Global Anti-VEGF Sales Volume by Application

4.3.1 Global Anti-VEGF Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Anti-VEGF Sales Volume, by Application (2019-2030)

4.3.3 Global Anti-VEGF Sales Volume, by Application (%) (2019-2030)

4.4 Global Anti-VEGF Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Anti-VEGF Sales Value by Region

5.1.1 Global Anti-VEGF Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Anti-VEGF Sales Value by Region (2019-2024)

5.1.3 Global Anti-VEGF Sales Value by Region (2025-2030)

5.1.4 Global Anti-VEGF Sales Value by Region (%), (2019-2030)

5.2 Global Anti-VEGF Sales Volume by Region

5.2.1 Global Anti-VEGF Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Anti-VEGF Sales Volume by Region (2019-2024)

5.2.3 Global Anti-VEGF Sales Volume by Region (2025-2030)

5.2.4 Global Anti-VEGF Sales Volume by Region (%), (2019-2030)

5.3 Global Anti-VEGF Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Anti-VEGF Sales Value, 2019-2030

5.4.2 North America Anti-VEGF Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Anti-VEGF Sales Value, 2019-2030

5.5.2 Europe Anti-VEGF Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Anti-VEGF Sales Value, 2019-2030

5.6.2 Asia Pacific Anti-VEGF Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Anti-VEGF Sales Value, 2019-2030

5.7.2 South America Anti-VEGF Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Anti-VEGF Sales Value, 2019-2030

5.8.2 Middle East & Africa Anti-VEGF Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Anti-VEGF Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Anti-VEGF Sales Value

6.2.1 Key Countries/Regions Anti-VEGF Sales Value, 2019-2030

6.2.2 Key Countries/Regions Anti-VEGF Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Anti-VEGF Sales Value, 2019-2030

6.3.2 United States Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Anti-VEGF Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Anti-VEGF Sales Value, 2019-2030

6.4.2 Europe Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Anti-VEGF Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Anti-VEGF Sales Value, 2019-2030

6.5.2 China Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.5.3 China Anti-VEGF Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Anti-VEGF Sales Value, 2019-2030

6.6.2 Japan Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Anti-VEGF Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Anti-VEGF Sales Value, 2019-2030

6.7.2 South Korea Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Anti-VEGF Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Anti-VEGF Sales Value, 2019-2030

6.8.2 Southeast Asia Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Anti-VEGF Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Anti-VEGF Sales Value, 2019-2030

6.9.2 India Anti-VEGF Sales Value by Type (%), 2023 VS 2030

6.9.3 India Anti-VEGF Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Amgen Inc.

7.1.1 Amgen Inc. Company Information

7.1.2 Amgen Inc. Introduction and Business Overview

7.1.3 Amgen Inc. Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Amgen Inc. Anti-VEGF Product Offerings

7.1.5 Amgen Inc. Recent Development

7.2 F. Hoffmann-La Roche Ltd.

7.2.1 F. Hoffmann-La Roche Ltd. Company Information

7.2.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview

7.2.3 F. Hoffmann-La Roche Ltd. Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.2.4 F. Hoffmann-La Roche Ltd. Anti-VEGF Product Offerings

7.2.5 F. Hoffmann-La Roche Ltd. Recent Development

7.3 Pfizer, Inc.

7.3.1 Pfizer, Inc. Company Information

7.3.2 Pfizer, Inc. Introduction and Business Overview

7.3.3 Pfizer, Inc. Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Pfizer, Inc. Anti-VEGF Product Offerings

7.3.5 Pfizer, Inc. Recent Development

7.4 Xbrane Biopharma AB

7.4.1 Xbrane Biopharma AB Company Information

7.4.2 Xbrane Biopharma AB Introduction and Business Overview

7.4.3 Xbrane Biopharma AB Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Xbrane Biopharma AB Anti-VEGF Product Offerings

7.4.5 Xbrane Biopharma AB Recent Development

7.5 Allergan, Bayer AG

7.5.1 Allergan, Bayer AG Company Information

7.5.2 Allergan, Bayer AG Introduction and Business Overview

7.5.3 Allergan, Bayer AG Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Allergan, Bayer AG Anti-VEGF Product Offerings

7.5.5 Allergan, Bayer AG Recent Development

7.6 Regeneron Pharmaceuticals Inc.

7.6.1 Regeneron Pharmaceuticals Inc. Company Information

7.6.2 Regeneron Pharmaceuticals Inc. Introduction and Business Overview

7.6.3 Regeneron Pharmaceuticals Inc. Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Regeneron Pharmaceuticals Inc. Anti-VEGF Product Offerings

7.6.5 Regeneron Pharmaceuticals Inc. Recent Development

7.7 Viatris Inc. (Mylan)

7.7.1 Viatris Inc. (Mylan) Company Information

7.7.2 Viatris Inc. (Mylan) Introduction and Business Overview

7.7.3 Viatris Inc. (Mylan) Anti-VEGF Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Viatris Inc. (Mylan) Anti-VEGF Product Offerings

7.7.5 Viatris Inc. (Mylan) Recent Development

8 Industry Chain Analysis

8.1 Anti-VEGF Industrial Chain

8.2 Anti-VEGF Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Anti-VEGF Sales Model

8.5.2 Sales Channel

8.5.3 Anti-VEGF Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Amgen Inc

F Hoffmann La Roche Ltd

Regeneron Pharmaceuticals Inc

List of Tables

Table 1. Anti-VEGF Market Trends

Table 2. Anti-VEGF Market Drivers & Opportunity

Table 3. Anti-VEGF Market Challenges

Table 4. Anti-VEGF Market Restraints

Table 5. Global Anti-VEGF Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Anti-VEGF Revenue Market Share by Company (2019-2024)

Table 7. Global Anti-VEGF Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Anti-VEGF Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Anti-VEGF Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Anti-VEGF Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Anti-VEGF Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Anti-VEGF

Table 13. Global Anti-VEGF Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Anti-VEGF Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Anti-VEGF Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Anti-VEGF Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Anti-VEGF Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Anti-VEGF Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Anti-VEGF Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Anti-VEGF Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Anti-VEGF Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Anti-VEGF Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Anti-VEGF Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Anti-VEGF Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Anti-VEGF Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Anti-VEGF Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Anti-VEGF Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Anti-VEGF Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Anti-VEGF Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Anti-VEGF Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Anti-VEGF Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Anti-VEGF Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Anti-VEGF Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Anti-VEGF Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Anti-VEGF Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Anti-VEGF Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Anti-VEGF Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Anti-VEGF Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Anti-VEGF Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Anti-VEGF Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Anti-VEGF Sales Value by Region (2019-2024) & (%)

Table 44. Global Anti-VEGF Sales Value by Region (2025-2030) & (%)

Table 45. Global Anti-VEGF Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Anti-VEGF Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Anti-VEGF Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Anti-VEGF Sales Volume by Region (2019-2024) & (%)

Table 49. Global Anti-VEGF Sales Volume by Region (2025-2030) & (%)

Table 50. Global Anti-VEGF Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Anti-VEGF Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Anti-VEGF Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Anti-VEGF Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Anti-VEGF Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Anti-VEGF Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Anti-VEGF Sales Volume, (2025-2030) & (K Units)

Table 57. Amgen Inc. Company Information

Table 58. Amgen Inc. Introduction and Business Overview

Table 59. Amgen Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Amgen Inc. Anti-VEGF Product Offerings

Table 61. Amgen Inc. Recent Development

Table 62. F. Hoffmann-La Roche Ltd. Company Information

Table 63. F. Hoffmann-La Roche Ltd. Introduction and Business Overview

Table 64. F. Hoffmann-La Roche Ltd. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. F. Hoffmann-La Roche Ltd. Anti-VEGF Product Offerings

Table 66. F. Hoffmann-La Roche Ltd. Recent Development

Table 67. Pfizer, Inc. Company Information

Table 68. Pfizer, Inc. Introduction and Business Overview

Table 69. Pfizer, Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Pfizer, Inc. Anti-VEGF Product Offerings

Table 71. Pfizer, Inc. Recent Development

Table 72. Xbrane Biopharma AB Company Information

Table 73. Xbrane Biopharma AB Introduction and Business Overview

Table 74. Xbrane Biopharma AB Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Xbrane Biopharma AB Anti-VEGF Product Offerings

Table 76. Xbrane Biopharma AB Recent Development

Table 77. Allergan, Bayer AG Company Information

Table 78. Allergan, Bayer AG Introduction and Business Overview

Table 79. Allergan, Bayer AG Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Allergan, Bayer AG Anti-VEGF Product Offerings

Table 81. Allergan, Bayer AG Recent Development

Table 82. Regeneron Pharmaceuticals Inc. Company Information

Table 83. Regeneron Pharmaceuticals Inc. Introduction and Business Overview

Table 84. Regeneron Pharmaceuticals Inc. Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Regeneron Pharmaceuticals Inc. Anti-VEGF Product Offerings

Table 86. Regeneron Pharmaceuticals Inc. Recent Development

Table 87. Viatris Inc. (Mylan) Company Information

Table 88. Viatris Inc. (Mylan) Introduction and Business Overview

Table 89. Viatris Inc. (Mylan) Anti-VEGF Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Viatris Inc. (Mylan) Anti-VEGF Product Offerings

Table 91. Viatris Inc. (Mylan) Recent Development

Table 92. Key Raw Materials Lists

Table 93. Raw Materials Key Suppliers Lists

Table 94. Anti-VEGF Downstream Customers

Table 95. Anti-VEGF Distributors List

Table 96. Research Programs/Design for This Report

Table 97. Key Data Information from Secondary Sources

Table 98. Key Data Information from Primary Sources

List of Figures

Figure 1. Anti-VEGF Product Picture

Figure 2. Global Anti-VEGF Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Anti-VEGF Sales Volume (2019-2030) & (K Units)

Figure 5. Global Anti-VEGF Sales Price (2019-2030) & (US$/Unit)

Figure 6. Anti-VEGF Report Years Considered

Figure 7. Global Anti-VEGF Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Anti-VEGF Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-VEGF Revenue in 2023

Figure 10. Anti-VEGF Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Avastin Picture

Figure 12. Lucentis Picture

Figure 13. Eylea Picture

Figure 14. Global Anti-VEGF Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Anti-VEGF Sales Value Market Share by Type, 2023 & 2030

Figure 16. Global Anti-VEGF Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 17. Global Anti-VEGF Sales Volume Market Share by Type, 2023 & 2030

Figure 18. Global Anti-VEGF Price by Type (2019-2030) & (US$/Unit)

Figure 19. Product Picture of Macular Edema

Figure 20. Product Picture of Diabetic Retinopathy

Figure 21. Product Picture of Retinal Vein Occlusion

Figure 22. Product Picture of Age-Related Macular Degeneration

Figure 23. Global Anti-VEGF Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 24. Global Anti-VEGF Sales Value Market Share by Application, 2023 & 2030

Figure 25. Global Anti-VEGF Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 26. Global Anti-VEGF Sales Volume Market Share by Application, 2023 & 2030

Figure 27. Global Anti-VEGF Price by Application (2019-2030) & (US$/Unit)

Figure 28. North America Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 29. North America Anti-VEGF Sales Value by Country (%), 2023 VS 2030

Figure 30. Europe Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 31. Europe Anti-VEGF Sales Value by Country (%), 2023 VS 2030

Figure 32. Asia Pacific Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 33. Asia Pacific Anti-VEGF Sales Value by Country (%), 2023 VS 2030

Figure 34. South America Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 35. South America Anti-VEGF Sales Value by Country (%), 2023 VS 2030

Figure 36. Middle East & Africa Anti-VEGF Sales Value (2019-2030) & (US$ Million)

Figure 37. Middle East & Africa Anti-VEGF Sales Value by Country (%), 2023 VS 2030

Figure 38. Key Countries/Regions Anti-VEGF Sales Value (%), (2019-2030)

Figure 39. Key Countries/Regions Anti-VEGF Sales Volume (%), (2019-2030)

Figure 40. United States Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 41. United States Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 42. United States Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 43. Europe Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 44. Europe Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 45. Europe Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 46. China Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 47. China Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 48. China Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 49. Japan Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 50. Japan Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 51. Japan Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 52. South Korea Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 53. South Korea Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 54. South Korea Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 55. Southeast Asia Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 56. Southeast Asia Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 57. Southeast Asia Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 58. India Anti-VEGF Sales Value, (2019-2030) & (US$ Million)

Figure 59. India Anti-VEGF Sales Value by Type (%), 2023 VS 2030

Figure 60. India Anti-VEGF Sales Value by Application (%), 2023 VS 2030

Figure 61. Anti-VEGF Industrial Chain

Figure 62. Anti-VEGF Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-26V13549

Mon Nov 11 00:00:00 UTC 2024

Add to Cart

Pharmaceutical Grade Sodium Hyaluronate - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-17N14065

Mon Nov 11 00:00:00 UTC 2024

Add to Cart

Pharmaceutical Fluid Bed System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-6Q14792

Fri Nov 08 00:00:00 UTC 2024

Add to Cart

Medical Microbial Incubators - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-30W13258

Thu Nov 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Anti-VEGF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-7Z13652

Anti-VEGF - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Anti-VEGF - Market Size

Anti-VEGF - Market

Report Scope

Scope of Anti-VEGF - Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Anti-VEGF - Market report?

What are the Application segmentation covered in the Anti-VEGF - Market report?

What are the Type segmentation covered in the Anti-VEGF - Market report?

FEATURED COMPANIES

RELATED REPORTS